Helus Pharma Appoints Michael Halstead as Chief Executive Officer

Helus Pharma announced the appointment of Michael Halstead as Chief Executive Officer, effective immediately. Halstead brings 25 years of pharmaceutical industry experience, including his recent role as President of Intra-Cellular Therapies during its $14.6 billion acquisition by Johnson & Johnson. The appointment comes as Helus Pharma completes enrollment in the APPROACH Phase 3 study of HLP003 for adjunctive treatment of Major Depressive Disorder, with topline data expected in Q4 2026.